Mod GRF 1-29

Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.

Mechanism of Action

Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity.

Typical Dosage (Research)

Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects.

Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version.

Side Effects & Risks

Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention.

Not FDA approved. May affect blood glucose. Long-term effects on pituitary function not fully characterized.

Who Uses Mod GRF 1-29

Those preferring pulsatile GH release mimicking natural patterns, individuals stacking with GHRPs, anti-aging protocols.